The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Open accessAbstract
BACKGROUND: The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially overcome or delay resistance to endocrine therapy in advanced breast cancer that is positive for hormone receptor (HR) and negative for human epidermal growth factor receptor 2 (HER2). METHODS: . RESULTS: for superiority). The median duration of follow-up was 15.3 months. After 18 months, the progression-free survival rate was 63.0% (95% confidence interval [CI], 54.6 to 70.3) in the ribociclib group and 42.2% (95% CI, 34.8 to 49.5) in the placebo group. In patients with measurable disease at baseline, the overall response rate was 52.7% and 37.1%, respectively (P<0.001). Common grade 3 or 4 adverse events that were reported in more than 10% of the patients in either group were neutropenia (59.3% in the ribociclib group vs. 0.9% in the placebo group) and leukopenia (21.0% vs. 0.6%); the rates of discontinuation because of adverse events were 7.5% and 2.1%, respectively. CONCLUSIONS: Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those receiving placebo plus letrozole, with a higher rate of myelosuppression in the ribociclib group. (Funded by Novartis Pharmaceuticals; ClinicalTrials.gov number, NCT01958021 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The last 2 years have seen the establishment of cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“substantial PFS benefit and good toxicity profile.36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These agents can be combined with an aromatase inhibitor (AI) or fulvestrant, and are effective in de novo or recurrent ABC, in first or second line, in cases of primary or secondary resistance, in postmenopausal and premenopausal women (the latter with ovarian function suppression/ablation), and in men (preferably with a luteinising hormone-releasing hormone agonist).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The median duration of exposure to trial treatment in the ribociclib group was 20.2 months (interquartile range, 7.4 to 45.1), which is 7 months longer than it was at the time of the primary analysis of progression-free survival. 10”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the primary and updated analyses of MONALEESA-2, progression-free survival was significantly longer with ribociclib plus letrozole than with placebo plus letrozole (median in updated analysis, 25.3 months vs. 16.0 months; hazard ratio for disease progression or death, 0.57; 95% confidence interval [CI], 0.46 to 0.70; P<0.001).”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [10]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Data for overall survival were immature at the time of the primary and updated analyses.”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the primary and updated analyses of MONALEESA-2, progression-free survival was significantly longer with ribociclib plus letrozole than with placebo plus letrozole (median in updated analysis, 25.3 months vs. 16.0 months; hazard ratio for disease progression or death, 0.57; 95% confidence interval [CI], 0.46 to 0.70; P<0.001).”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The use of CDK4/6 inhibitors (ribociclib, abemaciclib, and palbociclib) improved progression-free survival in this patient population, leading to regulatory approvals. 9-13”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In a previous analysis of this phase 3 trial, first-line ribociclib plus letrozole resulted in significantly longer progression-free survival than letrozole alone among postmenopausal patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.”
From Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer. (2022) · cites this paper as [10]
In the citing paper
“However, 10% of the patients treated with abemaciclib develop grade 3 diarrhea, which is very rare with the other two inhibitors (Asghar et al., 2015; Hortobagyi et al., 2016).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Hortobagyi et al., 2016
In the citing paper
“Abemaciclib appears to be better tolerated overall, with only 55% of patients experiencing significant adverse events (as compared to 70–80% with ribociclib and palbociclib) and only 21% with grade 3–4 neutropenia.”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Hortobagyi et al., 2016
In the citing paper
“Grade 3–4 neutropenia is observed in approximately 60% of patients taking palbociclib and ribociclib (Asghar et al., 2015; Hortobagyi et al., 2016).”
From CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought (2018) · cites this paper as Hortobagyi et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00613-0 · Cited by 1,827
Self-citationPalbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505270 · Cited by 1,590
Self-citationMECHANISMS OF ENDOCRINE RESISTANCE IN BREAST CANCER
Osborne, C., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,205
Di Leo, A., Jerusalem, G., Petruzelka, L., Torres, R., Bondarenko, I. N., Khasanov, R., Verhoeven, D., Pedrini, J. L., Smirnova, I., Lichinitser, M. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.8415 · Cited by 636
Anderson, W. F., Chatterjee, N., Ershler, W. B., & Brawley, O. W. (2002) · Breast Cancer Research and Treatment · doi:10.1023/a:1020299707510 · Cited by 589
Flagged first, then by citations
Research works printed but not linked: 2
- Infante JR, Clin Cancer Res
- Vuppalanchi R, Hepatology
Cited by
Sorted by citations
Items 601–700 of 1,000
Iorfida, M., Mazza, M., & Munzone, E. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s196240 · Cited by 29
Raimondi, L., Raimondi, F. M., Pietranera, M., Rocco, A. D., Benedetto, L. D., Miele, E., Lazzeroni, R., Cimino, G. G., & Spinelli, G. P. (2021) · Cancers · doi:10.3390/cancers13081928 · Cited by 26
Güven, D. C., & Şahin, T. K. (2024) · Breast Cancer Research and Treatment · doi:10.1007/s10549-023-07226-1 · Cited by 25
Reiter, F. P., Denk, G., Ziesch, A., Ofner, A., Wimmer, R., Hohenester, S. D., Schiergens, T. S., Spampatti, M. P., Ye, L., Itzel, T., et al. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00458-8 · Cited by 25
Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology
Gümüşay, Ö., Vitiello, P. P., Wabl, C. A., Corcoran, R. B., Bardelli, A., & Rugo, H. S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280845 · Cited by 29
Hui, R., BOER, R. D., Lim, E., Yeo, B. J., & Lynch, J. (2021) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13555 · Cited by 25
Ki67 and progesterone receptor status predicts sensitivity to palbociclib: a real-world study
Shao, X., Zheng, Y., Cao, W., Shen, X., Li, G., Chen, J., Huang, Y., Huang, P., Shi, L., Ye, W.-W., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1340 · Cited by 24
“Many phase III randomized trials have demonstrated the effectiveness of CDK4/6i in both first-line (9-12) and endocrine-resistant settings (12-14).”
BackgroundNaghavi‐Behzad, M., Vogsen, M., Vester, R. M., Olsen, M. M. B., Oltmann, H. R., Braad, P., Asmussen, J. T., Gerke, O., Vach, W., Kidholm, K., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-021-01654-w · Cited by 25
Lynce, F. C., Blackburn, M. J., Zhuo, R., Gallagher, C., Hahn, O. M., Abu-Khalaf, M. M., Mohebtash, M., Wu, T., Pohlmann, P. R., Dilawari, A. A., et al. (2021) · Cancer · doi:10.1002/cncr.33620 · Cited by 26
Conley, C. C., McIntyre, M., Pensak, N. A., Lynce, F. C., Graham, D. M. A., Ismail-Khan, R. R., Lopez, K., Vadaparampil, S. T., & O’Neill, S. C. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06518-2 · Cited by 27
“CDK4/6 inhibitors have nearly doubled progression-free survival for patients with HR + MBC [7, 8] and increase overall survival in certain clinical subgroups [9, 10], even when accounting for dose delays and reductions [11].”
BackgroundChiu, J. W. Y., Su, F., Joshi, M., Masuda, N., Ishikawa, T., Aruga, T., Zarate, J. P., Babbar, N., Balbin, O. A., & Yap, Y. S. (2023) · BMC Medicine · doi:10.1186/s12916-023-03017-z · Cited by 27
“All 3 MONALEESA trials, MONALEESA-2, MONALEESA-3, and MONALEESA-7, have reported significant progression-free survival (PFS) and overall survival (OS) benefits with ribociclib plus ET in the intention-to-treat populations [2–7].”
BackgroundSelf-citationAntonarelli, G., Salimbeni, B. T., Marra, A., Espósito, A., Locatelli, M., Trapani, D., Pescia, C., Fusco, N., Curigliano, G., & Criscitiello, C. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104148 · Cited by 26
Recent advancements of hydrogels in immunotherapy: Breast cancer treatment
Mondal, J., Chakraborty, K., Bunggulawa, E. J., An, J. M., Revuri, V., Nurunnabi, M., & Lee, Y.-K. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.003 · Cited by 25
Breast Cancer: 45 Years of Research and Progress
Hortobágyi, G. N. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00199 · Cited by 27
Use of new and emerging cancer drugs: what the cardiologist needs to know
Fabiani, I., Chianca, M., Aimo, A., Emdin, M., Dent, S. F., Fedele, A., Cipolla, C. M., & Cardinale, D. M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae161 · Cited by 26
SLC7A11 protects luminal A breast cancer cells against ferroptosis induced by CDK4/6 inhibitors
Cui, Y., Li, Y., Xu, Y., Liu, X., Kang, X., Zhu, J., Long, S., Han, Y., Xue, C., Sun, Z., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103304 · Cited by 30
Llombart‐Cussac, A., Harper-Wynne, C. L., Perelló, A., Hennequin, A., Fernández-Ortega, A., Colleoni, M. A., Marín, S., Quiroga, V., Médioni, J., Iranzo, V., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01865 · Cited by 29
Giugliano, F., Angelis, C. D., Pistilli, B., Viale, G., Bianchini, G., Giuliano, M., Malorni, L., Salimbeni, B. T., Espósito, A., Giordano, A., et al. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102980 · Cited by 26
Curigliano, G., Criscitiello, C., Espósito, A., Intra, M., & Minucci, S. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1318848 · Cited by 24
“comprehensive clinical package, including results of the phase III MONALEESA-2 trial [28].”
BackgroundMethodInfluentialSammons, S. L., Kornblum, N. S., & Blackwell, K. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0587-9 · Cited by 24
Self-citationKyrochristos, I. D., Ziogas, D. E., & Roukos, D. H. (2018) · Medicinal Research Reviews · doi:10.1002/med.21549 · Cited by 25
Malmgren, J. A., Hurlbert, M. S., Atwood, M. K., & Kaplan, H. G. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-05090-y · Cited by 24
Lerebours, F., Pulido, M., Fourme, E., Debled, M., Becette, V., Bonnefoi, H. R., Rivera, S., MacGrogan, G. M., Mouret‐Reynier, M., de Lara, C. T., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0733-x · Cited by 23
Self-citationLin, M., Chen, Y., Jin, Y., Hu, X., & Zhang, J. (2020) · Journal of Cancer · doi:10.7150/jca.48944 · Cited by 24
“After PALOMA-1, ribociclib-based MONALEESA-2[14], MONALEESA-3[12], MONALEESA-7[13] and palbociclib-based PALOMA-2[17], PALOMA-3[8] and abemaciclib-based MONARCH-2[15], MONARCH-3[16] all showed the superiority of CDK4/6 inhibitors-containing regimens over endocrine therapy alone.”
BackgroundMethodMasuda, N., Tamura, K., Yasojima, H., Shimomura, A., Sawaki, M., Lee, M.-J., Yuno, A., Trepel, J. B., Kimura, R., Nishimura, Y., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08973-4 · Cited by 24
Çetin, B., Wabl, C. A., & Gümüşay, Ö. (2022) · Future Oncology · doi:10.2217/fon-2021-0842 · Cited by 25
Liver Metastatic Breast Cancer: Epidemiology, Dietary Interventions, and Related Metabolism
Zuo, Q., Park, N. H., Lee, J. K., & Madak‐Erdogan, Z. (2022) · Nutrients · doi:10.3390/nu14122376 · Cited by 26
Roles of apelin/APJ system in cancer: Biomarker, predictor, and emerging therapeutic target
Chen, J., Li, Z., Zhao, Q., & Chen, L. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30845 · Cited by 24
“Ribociclib and Palbociclib can increase hormone receptor‐positive advanced breast cancer patients' duration of progression‐free survival (Hortobagyi et al., 2018).”
BackgroundTinterri, C., Sagona, A., Barbieri, E., Grimaldi, S. D. M., Jacobs, F., Zambelli, A., Trimboli, R. M., Bernardi, D., Vinci, V., & Gentile, D. (2022) · Cancers · doi:10.3390/cancers14246237 · Cited by 25
Kahraman, S., Erul, E., Seyyar, M., Gümüşay, Ö., Bayram, E., Demirel, B. Ç., Acar, Ö., Aksoy, S., Baytemür, N. K., Şahin, E., et al. (2023) · Future Oncology · doi:10.2217/fon-2022-1287 · Cited by 26
Shrestha, M., Wang, D., Ben‐David, Y., & Zacksenhaus, E. (2023) · Oncogenesis · doi:10.1038/s41389-023-00475-1 · Cited by 25
Cardoso, F., Rihani, J., Harmer, V., Harbeck, N., Casas, A., Rugo, H. S., Fasching, P. A., Moore, A., de Courcy, J., Pathak, P., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad207 · Cited by 27
CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer
Pan, Q., Sathe, A., Black, P. C., Goebell, P. J., Kamat, A. M., Schmitz‐Dräger, B. J., & Nawroth, R. (2017) · Bladder Cancer · doi:10.3233/blc-170105 · Cited by 24
“Based on these data, palbociclib and ribociclib have been approved or designated as breakthrough therapy, respectively, by the US FDA in this clinical setting [32, 34] The efficiency and toxicity between palbociclib and ribociclib are very similar.”
MethodJin, D., Tran, N., Thomas, N. J., & Tran, D. D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0223555 · Cited by 27
Inoue, K., Masuda, N., Iwata, H., Takahashi, M., Ito, Y., Miyoshi, Y., Nakayama, T., Mukai, H., van der Walt, J., Mori, J., et al. (2021) · Breast Cancer · doi:10.1007/s12282-021-01239-8 · Cited by 24
She, Y., Guo, Z., Zhai, Q., Liu, J., Du, Q., & Zhang, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1378090 · Cited by 24
The G 1 -S transition is promoted by Rb degradation via the E3 ligase UBR5
Zhang, S., Valenzuela, L. F., Zatulovskiy, E. A., Mangiante, L., Curtis, C. N., & Skotheim, J. M. (2024) · Science Advances · doi:10.1126/sciadv.adq6858 · Cited by 28
Zhang, Y., Zheng, L., Ma, L., Yin, F., Luo, Z., Li, S., Jiang, Y., Kong, L., & Wang, X. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01976 · Cited by 23
Thill, M., Zahn, M., Welt, A., Nusch, A., Zaiss, M. R., Engelken, K., Kaltenecker, G., Ringwald, K. G., Gratzke, K., Dille, S., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35296 · Cited by 26
Self-citationRaghavendra, A. S., Kettner, N. M., Kwiatkowski, D. N., Damodaran, S., Wang, Y., Ramirez, D. L., Gombos, D. S., Hunt, K. K., Shen, Y., Keyomarsi, K., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00722-1 · Cited by 23
Decreased ER dependency after acquired resistance to CDK4/6 inhibitors
Iida, M., Toyosawa, D., Nakamura, M., Tsuboi, K., Tokuda, E., Niwa, T., Ishida, T., & Hayashi, S. (2020) · Breast Cancer · doi:10.1007/s12282-020-01090-3 · Cited by 24
Franzoi, M. A., Saúde-Conde, R., Cristóvão‐Ferreira, S., Eiger, D., Awada, A. H., & de Azambuja, E. (2021) · The Breast · doi:10.1016/j.breast.2021.03.002 · Cited by 23
“Moreover, ECOG performance status 0/1 was an eligibility criteria for inclusion into the MONALEESA 2[34] and MONALEESA 7 trials [35].”
MethodRath, S., Elamarthi, P., Parab, P. A., Gulia, S., Nandhana, R., Mokal, S., Kembhavi, Y., Perumal, P., Bajpai, J., Ghosh, J., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0253722 · Cited by 24
Paoletti, C., Barlow, W. E., Cobain, E. F., Bergqvist, M., Mehta, R. S., Gralow, J. R., Hortobágyi, G. N., Albain, K. S., Pusztai, L., Sharma, P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1562 · Cited by 23
Neuroendocrine Neoplasms of the Breast: The Latest WHO Classification and Review of the Literature
Ozaki, Y., Miura, S., Oki, R., Morikawa, T., & Uchino, K. (2021) · Cancers · doi:10.3390/cancers14010196 · Cited by 25
Datta, J., Willingham, N., Manouchehri, J. M., Schnell, P., Sheth, M., David, J., Kassem, M. A. M., Wilson, T. A., Radomska, H. S., Coss, C. C., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.857590 · Cited by 24
“The advent of CDK4/6 inhibitors such as palbociclib (26, 27), ribociclib (28), and abemaciclib (29, 30) has doubled progression-free survival when used in combination with endocrine agents.”
BackgroundLee, J. S., Yost, S. E., Li, S. M., Cui, Y., Frankel, P. H., Yuan, Y., Schmolze, D., Egelston, C. A., Guo, W., Murga, M., et al. (2022) · Cancers · doi:10.3390/cancers14133159 · Cited by 24
Re, M. D., Crucitta, S., Omarini, C., Bargagna, I., Mongillo, M., Palleschi, M., Stucci, S., Meattini, I., D'Onofrio, R., Lorenzini, G., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.10.005 · Cited by 23
Krasniqi, E., Goeman, F., Pulito, C., Palcau, A. C., Ciuffreda, L., Lisa, F. S. D., Filomeno, L., Barba, M., Pizzuti, L., Cappuzzo, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314534 · Cited by 23
Karaçin, C., Öksüzoğlu, B. Ç., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., Selvi, O., Erdem, D., Avşar, E., Paksoy, N., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10609-8 · Cited by 23
“A significant PFS contribution of CDK inhibitors has been demonstrated in randomized clinical trials in which CDK4/6 inhibitors were used with endocrine therapies [5, 6].”
BackgroundHua, M., Xiong, F., Chong, S., Zhang, Z., Liu, Q., Hou, J., Zhang, Z., Gu, Z., Cui, X., Cui, Y., et al. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102827 · Cited by 26
CDK4/6 Inhibition on Glucose and Pancreatic Beta Cell Homeostasis in Young and Aged Rats
Sacaan, A. I., Thibault, S., Hong, M., Kondegowda, N. G., Nichols, T., Li, R., Rosselot, C., Evering, W., Fenutría, R., Vitsky, A., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0172 · Cited by 23
“This has been corroborated in the clinic, where neutropenia was identified not only with palbociclib, but also by two other CDK4/6 inhibitors, ribociclib and abemaciclib (12, 13).”
BackgroundPI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom
Schettini, F., Buono, G., Trivedi, M. V., Placido, S. D., Arpino, G., & Giuliano, M. (2017) · Breast Care · doi:10.1159/000481657 · Cited by 23
Freedman, R. A., & Tolaney, S. M. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4560-6 · Cited by 24
SEOM clinical guidelines in advanced and recurrent breast cancer (2018)
Chacón, J. I., de la Cruz‐Merino, L., Gregori, J. G., de Dueñas, E. M., Oliveira, M., Seguí, M. Á., Álvarez, I., Antolín, S., Bellet, M., & López‐Tarruella, S. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-018-02010-w · Cited by 24
Curigliano, G., de Azambuja, E., Lenihan, D. J., Calabró, M. G., Cardinale, D. M., & Cipolla, C. M. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0773 · Cited by 26
CDK 4/6 inhibitor successful rechallenge after limiting hepatic toxicity
Meynard, L., & Grellety, T. (2019) · The Breast Journal · doi:10.1111/tbj.13532 · Cited by 25
Ribociclib-Related Stevens–Johnson Syndrome: Oncologic Awareness, Case Report, and Literature Review
López-Gómez, V., Yarza, R., Muñoz‐González, H., Revilla, E., Enrech, S., González-Valle, O., Tolosa, P., & Ciruelos, E. (2019) · Journal of Breast Cancer · doi:10.4048/jbc.2019.22.e44 · Cited by 23
Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer
Loibl, S., & Furlanetto, J. (2021) · The Breast · doi:10.1016/j.breast.2021.12.008 · Cited by 23
“The MONALEESA-2 [23,24], MONALEESA-3 [25,26,33], and MONALEESA-7 [27,28] studies led to the approval of ribociclib in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy or in women who have received prior ET.”
BackgroundGastrointestinal Metastases From Lobular Breast Carcinoma: A Literature Review
Kioleoglou, Z., Georgaki, E., Koufopoulos, N. I., Köstek, O., Volakakis, N., Dimitriadou, A., & Kokkali, S. (2024) · Cureus · doi:10.7759/cureus.65852 · Cited by 22
“PALOMA-2 trial, in particular, showed significantly improved PFS (HR: 0.58; 95% CI: 0.46-0.72; p < 0.001) in both ILC patients (HR: 0.46) and patients who had visceral metastasis (HR: 0.63), whereas no data about ILC have been reported for ribociclib and abemaciclib [105,106].”
InfluentialUpdate Breast Cancer 2017 – Implementation of Novel Therapies
Lux, M. P., Janni, W., Hartkopf, A. D., Nabieva, N., Taran, F., Overkamp, F., Kolberg, H., Hadji, P., Tesch, H., Ettl, J., et al. (2017) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0043-122885 · Cited by 22
“In the last two years, a wealth of data has been published on the use of CDK4/6 inhibitors to treat patients with hormone receptor-positive, HER2-negative metastatic breast cancer [19 – 22].”
Self-citationGarcía, I. A., Garro, C., Fernández, E. A., & Soria, G. (2020) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2020.111693 · Cited by 22
Hepatotoxicity associated with ribociclib among breast cancer patients
Finnsdóttir, S. K., Sverrisdóttir, Á., & Bjornsson, E. S. (2020) · Acta Oncologica · doi:10.1080/0284186x.2020.1853228 · Cited by 23
A phase II trial of an alternative schedule of palbociclib and embedded serum TK1 analysis
Krishnamurthy, J., Luo, J. R., Suresh, R., Ademuyiwa, F. O., Rigden, C. E., Rearden, T. P., Clifton, K., Weilbaecher, K. N., Frith, A. E., Roshal, A., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00399-w · Cited by 21
Rubovszky, G., Kocsis, J., Boér, K., Chilingirova, N. P., Dank, M., Kahán, Z., Kaidarova, D., Kövér, E., Vertáková-Krakovská, B., Máhr, K., et al. (2022) · Pathology & Oncology Research · doi:10.3389/pore.2022.1610383 · Cited by 22
“Recommendations for Endocrine Therapies—In Postmenopause Patients With HR+ mBC As first-choice treatment for metastatic disease, combination of CDK4/6 inhibitors with NSAI significantly improvedmedian PFS (24–25 months) in all clinical trials [PALOMA-2 (77), MONALEESA-2 (78, 79), MONARCH-3 (80)] with acceptable side-e…”
BackgroundÇağlayan, D., Koçak, M. Z., Geredeli, Ç., Tatlı, A. M., Göksu, S. S., Eryılmaz, M. K., Araz, M., & Artaç, M. (2022) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-022-03435-7 · Cited by 22
Low, J. L., Lim, E. H., Bharwani, L. D., Wong, A. L. A., Wong, K., Ow, S. G. W., Lim, S. E., Lee, M., Choo, J. R. E., Lim, J. S. J., et al. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221139678 · Cited by 25
Ademuyiwa, F. O., Northfelt, D., O’Connor, T. L., Levine, E. G., Luo, J. R., Tao, Y., Hoog, J., Laury, M. L., Summa, T., Hammerschmidt, T., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-022-00504-z · Cited by 23
CDK13 phosphorylates the translation machinery and promotes tumorigenic protein synthesis
Wu, C., Xie, T., Guo, Y., Wang, D., Qiu, M., Han, R., Qing, G., Liang, K., & Liu, H. (2023) · Oncogene · doi:10.1038/s41388-023-02653-2 · Cited by 22
Thrombosis and cachexia in cancer: Two partners in crime?
Liz-Pimenta, J., Tavares, V., Neto, B. V., Santos, J., Guedes, C., Araújo, A., Khorana, A. A., & Medeiros, R. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103989 · Cited by 23
Ventricular Arrhythmia in Cancer Patients: Mechanisms, Treatment Strategies and Future Avenues
Agarwal, M. A., Sridharan, A., Pimentel, R., Markowitz, S. M., Rosenfeld, L. E., Fradley, M. G., & Yang, E. H. (2023) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2023.04 · Cited by 24
Shu, Y., Wang, L., Ding, Y., & Zhang, Q. (2023) · Drug Safety · doi:10.1007/s40264-023-01334-z · Cited by 23
The Evolving Pathways of the Efficacy of and Resistance to CDK4/6 Inhibitors in Breast Cancer
Gomes, I., Abreu, C., Costa, L., & Casimiro, S. (2023) · Cancers · doi:10.3390/cancers15194835 · Cited by 24
“The adverse events most observed in patients include neutropenia, hepatotoxicity and corrected QT interval (QTc) prolongation, which can also be controlled by dose interruption, dose reduction and additional symptomatic supportive treatment [31,38,39].”
Prat, A., Solovieff, N., André, F., O’Shaughnessy, J., Cameron, D., Janni, W., Sonke, G. S., Yap, Y. S., Yardley, D. A., Partridge, A. H., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0561 · Cited by 22
Self-citationVasseur, A., Cabel, L., Hego, C., Taka, W., Trabelsi‐Grati, O., Renouf, B., Lerebours, F., Loirat, D., Brain, E. G. C., Cottu, P. H., et al. (2024) · Oncogene · doi:10.1038/s41388-024-02986-6 · Cited by 24
Pascual, T., Fernández-Martínez, A., Agrawal, Y., Pfefferle, A. D., Chic, N., Brasó‐Maristany, F., González‐Farré, B., Paré, L., Villacampa, G. J., Saura, C., et al. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00625-7 · Cited by 22
Ibraheem, A. F., & Polite, B. N. (2017) · Cancer · doi:10.1002/cncr.31073 · Cited by 23
Fulvestrant: A Review in Advanced Breast Cancer Not Previously Treated with Endocrine Therapy
Deeks, E. D. (2017) · Drugs · doi:10.1007/s40265-017-0855-5 · Cited by 23
“monotherapy, although are associated with myelosuppression due to on-target CDK4/6 inhibition [39, 40], which may make them less suitable for some patients.”
BackgroundStearns, V., Brufsky, A., Verma, S., Cotter, M. J., Lu, D. R., Dequen, F., & Joy, A. A. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.07.007 · Cited by 23
Self-citationRibociclib in HR+/HER2− Advanced or Metastatic Breast Cancer Patients
Rascon, K., Flajc, G., Angelis, C. D., Liu, X., Trivedi, M. V., & Ekinci, E. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018817904 · Cited by 24
Seront, E., Schmitz, S., Papier, M., Maanen, A. G. V., Henry, S., Lonchay, C., Rottey, S., van Caloen, G., & Machiels, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00155 · Cited by 22
“The escalation phase of this study identified 600mg daily for 3 weeks on followed by 1 week off as the MTD of ribociclib in combination with cetuximab, which is also the recommended dose in metastatic breast cancer in association endocrine therapy (16).”
BackgroundMethodRibociclib, a CDK 4/6 inhibitor, plus endocrine therapy in Asian women with advanced breast cancer
Yap, Y. S., Chiu, J. W. Y., Ito, Y., Ishikawa, T., Aruga, T., Kim, S. J., Toyama, T., Saeki, T., Saito, M., Gounaris, I., et al. (2020) · Cancer Science · doi:10.1111/cas.14554 · Cited by 20
Self-citationOno, M., Oba, T., Shibata, T., & Ito, K. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03722-3 · Cited by 23
TP53-associated early breast cancer: new observations from a large cohort
Sandoval, R. L., Bottosso, M., Li, T., Polidorio, N., Bychkovsky, B., Verret, B., Gennari, A., Hyman, S., Achatz, M. I., Caron, O., et al. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae074 · Cited by 23
Self-citationŞahin, T. K., Kavgacı, G., Güven, D. C., & Aksoy, S. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102956 · Cited by 24
Schütz, F., Fasching, P. A., Welslau, M., Hartkopf, A. D., Wöckel, A., Lux, M. P., Janni, W., Ettl, J., Lüftner, D., Belleville, E., et al. (2019) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1001-9925 · Cited by 21
Self-citationWilson, B. E., Mok, K., Kiely, B. E., Nguyen, R. H., & Moylan, E. J. (2019) · Internal Medicine Journal · doi:10.1111/imj.14629 · Cited by 21
Shimoi, T., Sagara, Y., Hara, F., Toyama, T., & Iwata, H. (2020) · Breast Cancer · doi:10.1007/s12282-020-01054-7 · Cited by 23
“Hortobagyi 2016 [15] MONALEESA 2 RIBO+LETb 334 Not reached 87 (26.”
Zhu, W., & Xu, B. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0795-4 · Cited by 21
Shariati, M., Evans, K. W., Zheng, X., Bristow, C. A., Ng, P. K., Rizvi, Y. Q., Tapia, C., Yang, F., Carugo, A., Heffernan, T. P., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01819-0 · Cited by 20
“In the phase III trial of MONALEESA-2 (NCT 01958021), the combination of CDK4/6 inhibitor ribociclib with letrozole was compared to placebo and letrozole for treatment in postmenopausal women with HR-positive, HER2-negative advanced breast cancer [34].”
MethodAhmed, M. M., Fatima, F., Alali, A. S., Kalam, M. A., Alhazzani, K., Bhatia, S., Alshehri, S., & Ghoneim, M. M. (2022) · Adsorption Science & Technology · doi:10.1155/2022/1922263 · Cited by 22
RetractedXu, H., Wang, Y., Han, Y., Wu, Y., Wang, J., & Xu, B. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.956464 · Cited by 21
“06 II Pictilisib + Fulvestrant (41) Placebo + Fulvestrant (20) 0(12)/1(27)/ 2(20)/≥3(41) 0(10)/1(35)/ 2(25)/≥3(30) 17 25 51 50”
Choong, G. M. Y., Liddell, S. S., Ferre, R. A. L., O'Sullivan, C. C., Ruddy, K. J., Haddad, T. C., Hobday, T. J., Peethambaram, P. P., Liu, M., Goetz, M. P., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06713-1 · Cited by 22
Zhou, J., Wu, X., Zhang, H., Wang, X., Yuan, Y., Zhang, S., Jiang, Z., & Wang, T. (2022) · The Breast · doi:10.1016/j.breast.2022.10.018 · Cited by 21
Systematic review of the management of brain metastases from hormone receptor positive breast cancer
Jusino, S., Fadul, C. E., & Dillon, P. M. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04276-9 · Cited by 22
“Ribociclib was FDA-approved based on the results from the MONALEESA-2 [27, 28] and MONALEESA-3 [29] studies.”
MethodAl-Ziftawi, N. H., Elazzazy, S., Alam, M. F., Shafie, A. A., Hamad, A. A., Bbujassoum, S., & Ibrahim, M. I. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1203684 · Cited by 23
New agents for endocrine resistance in breast cancer
Maurer, C., Martel, S., Zardavas, D., & Ignatiadis, M. (2017) · The Breast · doi:10.1016/j.breast.2017.04.007 · Cited by 21
Stevens-Johnson syndrome–like eruption from palbociclib in a patient with metastatic breast cancer
Karagounis, T. K., Vallurupalli, M., Nathan, N. R., Nazarian, R. M., Vedak, P., Spring, L. M., & Chen, S. T. (2018) · JAAD Case Reports · doi:10.1016/j.jdcr.2017.12.015 · Cited by 22
Palbociclib enhances activin‐ SMAD ‐induced cytostasis in estrogen receptor‐positive breast cancer
Harada, M., Morikawa, M., Ozawa, T., Kobayashi, M., Tamura, Y., Takahashi, K., Tanabe, M., Tada, K., Seto, Y., Miyazono, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13841 · Cited by 21
Peguero, J. A., Sohal, D. P. S., O’Neil, B. H., Safran, H. P., Kelly, K. L., Grilley‐Olson, J. E., Subbiah, V., Nadauld, L. D., Purkayastha, D., Stealey, E., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00383 · Cited by 21
Metadata
- Authors
- Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., Janni, W., Verma, S., Conte, P., Arteaga, C. L., Cameron, D. A., Petrakova, K., Hart, L. L., Villanueva, C., Chan, A., Jakobsen, E., Nusch, A., Burdaeva, O., Grischke, E.-M., Alba, E., Wist, E., Marschner, N., Favret, A. M., Yardley, D., Bachelot, T., Tseng, L.-M., Blau, S., Xuan, F., Souami, F., Miller, M., Germa, C., Hirawat, S., & O’Shaughnessy, J.
- Affiliations
- From the University of Texas M.D. Anderson Cancer Center, Houston (G.N.H.), and Texas Oncology–Baylor Charles A. Sammons Cancer Center and the U.S. Oncology Network, Dallas (J.O.) — all in Texas; Davidoff Center, Rabin Medical Center, Tel Aviv University, Tel Aviv (S.M.S.), and Sheba Medical Center, Ramat Gan (S.P.-S.) — both in Israel; the Sarah Cannon Research Institute (H.A.B., D.Y.), Vanderbilt–Ingram Cancer Center (C.L.A.), and Tennessee Oncology (D.Y.) — all in Nashville; National Cancer Center...
- The University of Texas MD Anderson Cancer Center (US)
- Université Paris-Sud (FR)
- Oslo University Hospital (NO)
- Novartis (Switzerland) (CH)
- ORCID
- Stemmer, Salomon M.
- Burris, Howard A.
- Yap, Yoon-Sim
- Sonke, Gabe S.
- Campone, Mario
- Blackwell, Kimberly L.
- André, Fabrice
- Winer, Eric P.
- Janni, Wolfgang
- Verma, Sunil
- Conte, Pierfranco
- Arteaga, Carlos L.
- Cameron, David A.
- Chan, Arlene
- Jakobsen, Erik
- Grischke, Eva-Maria
- Alba, Emilio
- Wist, Erik
- Marschner, Norbert
- Favret, Anne M.
- Yardley, Denise
- Bachelot, Thomas
- Tseng, Ling-Ming
- Blau, Sibel
- Xuan, Fengjuan
- Miller, Michelle
- Germa, Caroline
- O’Shaughnessy, Joyce
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-11-03
- Volume
- 375
- Issue
- 18
- Pages
- 1738-1748
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2528767298
- Cited by
- 2,039
- References
- 24
- Citations by year
- 2026: 167 · 2025: 218 · 2024: 203 · 2023: 214 · 2022: 187 · 2021: 247 · 2020: 206 · 2019: 173 · 2018: 237 · 2017: 166 · 2016: 17
- FWCI
- 176.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Spectrum Pharmaceuticals
- Celgene
- Exelixis
- Celldex Therapeutics
- TG Therapeutics
- Astex Pharmaceuticals
- Agios Pharmaceuticals
- Jounce Therapeutics
- Mersana Therapeutics
- Incyte
- G1 Therapeutics
- Eisai
- Astellas Pharma
- Ipsen
- Genentech
- Chugai Pharmaceutical
- Novartis Institutes for BioMedical Research
- Loxo Oncology
- Topics
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Keywords
- ribociclib, CDK4/6 inhibitors, hormone receptor-positive HER2-negative breast cancer, advanced breast cancer, first-line therapy, letrozole, endocrine therapy resistance, progression-free survival, myelosuppression, neutropenia, leukopenia
- MeSH terms
- Letrozole, Adult, Aged, Aged, 80 and over, Aminopyridines, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Double-Blind Method, Drug Administration Schedule, Female, Humans, Middle Aged, Neoplasm Staging, Nitriles, Purines, Receptors, Estrogen, Receptors, Progesterone, Triazoles, Disease-Free Survival, Erb-b2 Receptor Tyrosine Kinases, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
